Cited by 122Fibromyalgia and Chronic Fatigue Syndrome ResearchPain Mechanisms and TreatmentsPain Management and Treatment

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Current and Emerging Pharmacotherapy for Fibromyalgia

Open access

Tzadok, Roie, Ablin, Jacob N.·2020·Pain Research and Management

DOI 10.1155/2020/6541798PMC PMC7036118

Open this paper in CoChat — free account Open PDF

Abstract

Introduction . Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered . The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion . Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1155/2020/6541798

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Evidence for a central component of post-injury pain hypersensitivity
Woolf, C. J. (1983) · Nature · doi:10.1038/306686a0 · Cited by 2,157
EULAR revised recommendations for the management of fibromyalgia
Macfarlane, G. J., Kronisch, C., Dean, L. E., Atzeni, F., Häuser, W., Fluß, E., Choy, E., Kosek, E., Amris, K., Branco, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209724 · Cited by 1,566 · cited 2×
“did not find them of proven benefit [70], and hence, they are not included in the revised 2016 EULAR recommendations [6].”
Background
The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Insel, T. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020138 · Cited by 1,472 · cited 1×
“One example of such an initiative is the Research Domain Criteria (RDoC) of the NIAMH, which attempts to create an integrative framework for the research, classification, and future treatment of mental disorders, while incorporating evidence ranging from genomics through circuits, with the goal of eventually developin…”
Background
EULAR evidence-based recommendations for the management of fibromyalgia syndrome
Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A. P., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071522 · Cited by 752 · cited 1×
“Despite the EULAR recommendations for management of FMS from 2008, recommending the consideration of dopamine agonists [8], a meta-analysis conducted by Sommer et al.”
Method
Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states
Yarnitsky, D. (2010) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32833c348b · Cited by 745 · cited 1×
“+us, medications that modulate levels of these neurotransmitters in the CNS have the potential to improve CPM and reduce central sensitization [40, 41].”
Background
Practical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663 · cited 1×
“+e THC:CBD therefore determines the product’s overall effect [71].”
Background
Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double‐blind, placebo‐controlled trial
Crofford, L. J., Rowbotham, M. C., Mease, P. J., Russell, I. J., Dworkin, R. H., Corbin, A. E., Young, J. P., LaMoreaux, L., Martin, S. A., Sharma, U., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20983 · Cited by 652 · cited 1×
“However, compared to placebo, it was not found to significantly improve complaints of fatigue in some trials, and none of the trials indicated any improvement in depressive symptoms [20, 21, 53].”
Result
Central Sensitivity Syndromes: A New Paradigm and Group Nosology for Fibromyalgia and Overlapping Conditions, and the Related Issue of Disease versus Illness
Yunus, M. B. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2007.09.003 · Cited by 648
Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity
Napadow, V., LaCount, L., Park, K., As‐Sanie, S., Clauw, D. J., & Harris, R. E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27497 · Cited by 645 · cited 2×
“Indeed, increased connectivity between different brain areas is a known phenomenon in FMS [46].”
Background
Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition
Julien, N., Goffaux, P., Arsenault, P., & Marchand, S. (2005) · Pain · doi:10.1016/j.pain.2004.12.032 · Cited by 634 · cited 1×
“In humans, such two descending pain inhibitory pathways exist: the noradrenaline/serotonin-mediated pathway and the opioidmediated one [62].”
Background
Decreased Central μ-Opioid Receptor Availability in Fibromyalgia
Harris, R. E., Clauw, D. J., Scott, D., McLean, S. A., Gracely, R. H., & Zubieta, J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2849-07.2007 · Cited by 525 · cited 1×
“Reduced availability was inversely correlated with clinical pain ratings [64].”
Background
Mechanism of action of memantine
Johnson, J. M., & Kotermanski, S. E. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.09.007 · Cited by 500 · cited 1×
“Memantine, another receptor antagonist, was suggested to be useful because of its ability to reduce neurotoxicity caused by high levels of glutamate found in different brain areas of FMS patients [31, 32].”
Background
The Prevalence of Fibromyalgia in the General Population: A Comparison of the American College of Rheumatology 1990, 2010, and Modified 2010 Classification Criteria
Jones, G. T., Atzeni, F., Beasley, M., Flüß, E., Sarzi‐Puttini, P., & Macfarlane, G. J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38905 · Cited by 468 · cited 1×
“Fibromyalgia syndrome (FMS) is a common pain disorder, characterized by chronic generalized pain, with a population-estimated prevalence of 1–5% [1].”
Background
2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary
Fitzcharles, M.-A., Ste-Marie, P. A., Goldenberg, D. L., Pereira, J. X., Abbey, S., Choinière, M., Ko, G., Moulin, D. E., Panopalis, P., Proulx, J., et al. (2013) · Pain Research and Management · doi:10.1155/2013/918216 · Cited by 409
Fibromyalgia patients show an abnormal dopamine response to pain
Wood, P. B., Schweinhardt, P., Jaeger, E., Dagher, A., Hakyemez, H., Rabiner, E. A., Bushnell, M. C., & Chizh, B. A. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05623.x · Cited by 406 · cited 1×
“Evidence indicating involvement of dopaminergic pathways in the pathophysiology of FMS has led to attempts to develop medications intervening in dopaminergic metabolism [68].”
Background
Nabilone for the treatment of pain in fibromyalgia.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.002 · Cited by 384 · cited 1×
“reported a reduction in pain, as well as level of anxiety, and an improved quality of life when using nabilone in comparison with placebo [26].”
Background
The role of NMDA and non-NMDA excitatory amino acid receptors in the excitation of primate spinothalamic tract neurons by mechanical, chemical, thermal, and electrical stimuli
Dougherty, P. M., Paleček, J., Palečková, V., Sorkin, L. S., & Willis, W. H. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-08-03025.1992 · Cited by 367 · cited 1×
“Activated by a variety of agonists, including substance P and neurokinin, it is known to be involved in the pathogenesis of central sensitization [80], a trait for which efforts were made to develop NMDA antagonists as therapeutic options for FMS, as well as other disorders resulting from central sensitization.”
Background
Naloxone Protects Rat Dopaminergic Neurons against Inflammatory Damage through Inhibition of Microglia Activation and Superoxide Generation
Liu, B., Du, L., & Hong, J.-S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39275-4 · Cited by 347 · cited 1×
“Inhibition of microglial activation by naltrexone or naloxone therefore has an anti-inflammatory effect through the decrease in production of neurotoxic chemicals [66, 67], which is suggested to contribute to its analgesic effect [25].”
Background
An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia
van de Donk, T., Niesters, M., Kowal, M. A., Olofsen, E., Dahan, A., & van Velzen, M. (2018) · Pain · doi:10.1097/j.pain.0000000000001464 · Cited by 331 · cited 1×
“+ey found that THC-containing products increased the pain threshold, whereas CBD-containing products increased plasma-THC levels but diminished THC analgesic effect [75].”
Background
Elevated insular glutamate in fibromyalgia is associated with experimental pain
Harris, R. E., Sundgren, P. C., Craig, A. D., Kirshenbaum, E., Sen, A., Napadow, V., & Clauw, D. J. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24849 · Cited by 328 · cited 1×
“Memantine, another receptor antagonist, was suggested to be useful because of its ability to reduce neurotoxicity caused by high levels of glutamate found in different brain areas of FMS patients [31, 32].”
Background
The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial
Ware, M. A., Fitzcharles, M.-A., Joseph, L., & Shir, Y. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181c76f70 · Cited by 324
The Science of Fibromyalgia
Clauw, D. J., Arnold, L. M., & McCarberg, B. H. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0206 · Cited by 314
Brain glial activation in fibromyalgia – A multi-site positron emission tomography investigation
Albrecht, D. S., Forsberg, A., Sandström, A., Bergan, C., Kadetoff, D., Protsenko, E., Lampa, J., Lee, Y. C., Höglund, C. O., Catana, C., et al. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.09.018 · Cited by 310
Narrative Review: The Pathophysiology of Fibromyalgia
Abeles, A. M., Pillinger, M. H., Solitar, B. M., & Abeles, M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-10-200705150-00006 · Cited by 284 · cited 1×
“Other neurotransmitters, including GABA, cannabinoid receptors, substance P, NGF, and opioid receptors participate in this complex modulation of pain transmission [42], therefore functioning as optional therapeutic targets.”
Background
A 14-week, Randomized, Double-Blinded, Placebo-Controlled Monotherapy Trial of Pregabalin in Patients With Fibromyalgia
Arnold, L. M., Russell, I. J., Diri, E. W., Duan, W. R., Young, J. P., Sharma, U., Martin, S. A., Barrett, J. A., & Haig, G. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.03.013 · Cited by 277
Brief Report: Decreased intrinsic brain connectivity is associated with reduced clinical pain in fibromyalgia
Napadow, V., Kim, J., Clauw, D. J., & Harris, R. E. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34412 · Cited by 276
Treatment of fibromyalgia with cyclobenzaprine: A meta‐analysis
Tofferi, J. K., Jackson, J. L., & O’Malley, P. G. (2004) · Arthritis Care & Research · doi:10.1002/art.20076 · Cited by 275 · cited 1×
“A systematic review of the literature reported that it has a moderate benefit in improving sleep disturbances and only a mild improvement in pain [17].”
Background
Systematic review with meta-analysis: cytokines in fibromyalgia syndrome
Üçeyler, N., Häuser, W., & Sommer, C. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-245 · Cited by 260
Effectiveness of therapeutic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomized clinical trials
Sosa-Reina, M. D., Nunez-Nagy, S., Gallego-Izquierdo, T., Pecos-Martín, D., Monserrat, J., & Álvarez-Mon, M. (2017) · BioMed Research International · doi:10.1155/2017/2356346 · Cited by 246
Treatment of fibromyalgia syndrome with gabapentin and pregabalin – A meta-analysis of randomized controlled trials
Häuser, W., Bernardy, K., Üçeyler, N., & Sommer, C. (2009) · Pain · doi:10.1016/j.pain.2009.05.014 · Cited by 243 · cited 1×
“A meta-analysis of randomized controlled trials regarding both pregabalin and gabapentin further emphasized their effect in improving pain, fatigue, sleep, and overall quality of life, in addition to their lack of effect on depressive symptoms and relatively nonsubstantial effect on anxiety [22].”
Background
Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
Marks, D., Shah, M., Patkar, A. A., Masand, P. S., Park, G., & Pae, C. (2009) · Current Neuropharmacology · doi:10.2174/157015909790031201 · Cited by 237 · cited 1×
“Despite the theoretical assumption, that the combined inhibition of serotonin and noradrenaline is more efficacious than selective serotonin augmentation vis-à-vis the inhibition of pain [51], the use of this class of drugs is recommended in practice guidelines [8–10, 15].”
Background
Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome – A systematic review and meta-analysis of randomized controlled trials
Bernardy, K., Klose, P., Welsch, P., & Häuser, W. (2018) · European Journal of Pain · doi:10.1002/ejp.1121 · Cited by 217 · cited 1×
“NYX-2925 ((2S,3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo2,5-diazaspiro[3,4]octan-2-yl)butanamide) is a new NMDA receptor modulator which was shown by Khan et al.”
Background
Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study
Younger, J., & Mackey, S. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00613.x · Cited by 216 · cited 1×
“+e beneficial effect of naltrexone on fibromyalgia symptoms was shown by Youner and Mackey in a pilot study in 2009 [24], with a randomized controlled trial published in 2013, finding it to be superior to placebo in reducing pain and associated depressive symptoms [25].”
Background
Low‐dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double‐blind, placebo‐controlled, counterbalanced, crossover trial assessing daily pain levels
Younger, J., Noor, N., McCue, R., & Mackey, S. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37734 · Cited by 209 · cited 2×
“Inhibition of microglial activation by naltrexone or naloxone therefore has an anti-inflammatory effect through the decrease in production of neurotoxic chemicals [66, 67], which is suggested to contribute to its analgesic effect [25].”
Background
The Role of Antidepressants in the Management of Fibromyalgia Syndrome
Häuser, W., Wolfe, F., Tölle, T. R., Üçeyler, N., & Sommer, C. (2012) · CNS Drugs · doi:10.2165/11598970-000000000-00000 · Cited by 208 · cited 1×
“+e effect size for improvement in sleep disorders was found to be nonsubstantial [16].”
Background
The endogenous cannabinoid system and its role in nociceptive behavior
Cravatt, B. F., & Lichtman, A. H. (2004) · Journal of Neurobiology · doi:10.1002/neu.20080 · Cited by 203 · cited 1×
“+eir agonists act along sensory pathways as modulators of pain [72].”
Background
Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia
Harris, R. E., Sundgren, P. C., Pang, Y., Hsu, M. C., Petrou, M., Kim, S., McLean, S. A., Gracely, R. H., & Clauw, D. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23223 · Cited by 199 · cited 1×
“+ese high glutamate levels were found to be related to the severity of FMS symptoms [81].”
Background
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome
Häuser, W., Urrútia, G., Tort, S., Üçeyler, N., & Walitt, B. T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010292 · Cited by 169 · cited 2×
“A meta-analysis reviewing five different studies regarding duloxetine and five different studies regarding and milnacipran showed that these drugs had positive effects on pain and patient-perceived clinical improvement [12].”
Employees With Fibromyalgia: Medical Comorbidity, Healthcare Costs, and Work Loss
White, L. A., Birnbaum, H. G., Kaltenboeck, A., Tang, J., Mallett, D., & Robinson, R. L. (2008) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0b013e31815cff4b · Cited by 168 · cited 1×
“Comorbid conditions, including mood disorders, anxiety, headaches, irritable bowel syndrome, sleep disturbances, and chronic fatigue syndrome, are found in a large percentage of FMS patients [2, 44, 45].”
Background
Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain
Baraniuk, J. N., Whalen, G., Cunningham, J., & Clauw, D. J. (2004) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-5-48 · Cited by 167 · cited 1×
“suggested an excess of endogenous opioids in FMS [63].”
Background
Treatment of Fibromyalgia Syndrome: Recommendations of Recent Evidence-Based Interdisciplinary Guidelines with Special Emphasis on Complementary and Alternative Therapies
Ablin, J. N., Fitzcharles, M., Buskila, D., Shir, Y., Sommer, C., & Häuser, W. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/485272 · Cited by 161
Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions
Aaron, L. A., & Buchwald, D. (2003) · Best Practice & Research Clinical Rheumatology · doi:10.1016/s1521-6942(03)00033-0 · Cited by 152 · cited 1×
“Comorbid conditions, including mood disorders, anxiety, headaches, irritable bowel syndrome, sleep disturbances, and chronic fatigue syndrome, are found in a large percentage of FMS patients [2, 44, 45].”
Background
Cannabinoids for fibromyalgia
Walitt, B. T., Klose, P., Fitzcharles, M., Phillips, T., & Häuser, W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011694.pub2 · Cited by 147 · cited 1×
“concluded that no convincing evidence suggests that nabilone is useful in treating people with FMS [28].”
Background
Emerging Trends in Pain Modulation by Metabotropic Glutamate Receptors
Pereira, V., & Goudet, C. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00464 · Cited by 138 · cited 1×
“Central sensitization of pain transmission pathways is associated with hyperexcitability of the glutamatergic system, which leads symptoms observed in persons suffering from chronic pain [79].”
Background
Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of Life
Fiz, J., Durán, M., Capellà, D., Abelló, J. C., & Farré, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018440 · Cited by 136 · cited 1×
“reported a significant relief in pain two hours after consumption [74].”
Background
Efficacy and Safety of Lacosamide in Diabetic Neuropathic Pain
Wymer, J. P., Simpson, J. N., Sen, D. L., & Bongardt, S. (2009) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e318196d2b6 · Cited by 136 · cited 1×
“It was also found effective in a placebo-controlled, doubleblind trial for treating neuropathic pain [55].”
Background
Safety and Efficacy of Medical Cannabis in Fibromyalgia
Sagy, I., Schleider, L. B., Abu‐Shakra, M., & Novack, V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060807 · Cited by 133 · cited 1×
“+e researchers showed a significant reduction in average pain intensity, sleep disturbance, and depression-related symptoms [76].”
Background
Resting state connectivity correlates with drug and placebo response in fibromyalgia patients
Schmidt-Wilcke, T., Ichesco, E., Hampson, J. P., Kairys, A., Peltier, S., Harte, S., Clauw, D. J., & Harris, R. E. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.09.007 · Cited by 122 · cited 2×
“Once such an integrative matrix is put in place, future clinicians will hopefully be able to treat specific patients based on their individual genetic (and pharmcogenetic) characteristics, together with an individualized analysis of connectivity patterns (notably, initial research in this direction is already underway…”
Result
An update on pharmacotherapy for the treatment of fibromyalgia
Calandre, E. P., Rico‐Villademoros, F., & Slim, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1047343 · Cited by 119 · cited 5×
“Several randomized controlled trials, meta-analysis [11, 12]”
BackgroundInfluential
Management of fibromyalgia: practical guides from recent evidence-based guidelines
Häuser, W., Ablin, J. N., Perrot, S., & Fitzcharles, M. (2017) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3877 · Cited by 109
Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial
Gür, A., Karakoç, M., Nas, K., Çevik, R., Saraç, A. J., & Ataoğlu, S. (2002) · Rheumatology International · doi:10.1007/s00296-002-0221-z · Cited by 107
Effects of Bedtime Very Low Dose Cyclobenzaprine on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome: A Double-blind Randomized Placebo-controlled Study
Moldofsky, H., HARRIS, H. W., Archambault, W. T., KWONG, T., & Lederman, S. M. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110194 · Cited by 97 · cited 1×
“have previously shown that bedtime very low doses of cyclobenzaprine were shown to significantly improve pain and sleep in patients with a specific sleep architecture [18].”
Background
Lacosamide for neuropathic pain and fibromyalgia in adults
Hearn, L., Derry, S., & Moore, R. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009318.pub2 · Cited by 95
Evaluation of Reboxetine, a Noradrenergic Antidepressant, for the Treatment of Fibromyalgia and Chronic Low Back Pain
Krell, H. V., Leuchter, A. F., Cook, I. A., & Abrams, M. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.5.379 · Cited by 94 · cited 1×
“Selective noradrenaline reuptake inhibitors (NRIs), such as reboxetine and its enantiomer esreboxetine, were also suggested as possible treatments for FMS, while the body of evidence regarding the efficacy of reboxetine is rather sporadic and is based mostly on case reports [13], esreboxetine was shown to reduce pain,…”
Background
Ethanol-enhanced GABA release: A focus on G protein-coupled receptors
Kelm, M. K., Criswell, H. E., & Breese, G. R. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.09.003 · Cited by 90 · cited 12×
“+e two main members of this family of drugs, pregabalin and gabapentin, act by binding to the alpha2delta subunit of voltage-gated calcium channels in the CNS. Originally used as anticonvulsants, they are currently mainly used for the treatment of chronic pain [11].”
BackgroundInfluential
Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up
Oliván‐Blázquez, B., Herrera‐Mercadal, P., Puebla‐Guedea, M., Pérez‐Yus, M., Andres, E. M., Fayed, N. M., del Hoyo, Y. L., Magallón-Botaya, R. M., Roca, M., & García‐Campayo, J. (2014) · Pain · doi:10.1016/j.pain.2014.09.004 · Cited by 88 · cited 1×
“A double-blind, randomized-controlled trial published in 2014 found memantine to achieve a significant reduction in pain [33], with another hypothesis suggesting the combined use of pregabalin and memantine to concomitantly affect voltage-gated calcium channels and NMDA receptors, as a possible therapeutic approach [8…”
Background
A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
Ohta, H., Oka, H., Usui, C., Ohkura, M., Suzuki, M., & Nishioka, K. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4056 · Cited by 87 · cited 1×
“However, compared to placebo, it was not found to significantly improve complaints of fatigue in some trials, and none of the trials indicated any improvement in depressive symptoms [20, 21, 53].”
Result
Mirogabalin: First Global Approval
Deeks, E. D. (2019) · Drugs · doi:10.1007/s40265-019-01070-8 · Cited by 80 · cited 1×
“A newer gabapentinoid, mirogabalin (DS-5565) was shown to have analgesic qualities in animal models of both central and peripheral neuropathies [56], while approved for the treatment of peripheral neuropathy in Japan, its development as a treatment modality for FMS in the USA and Europe was stopped after it failed in…”
Background
Medikamentöse Therapie des Fibromyalgiesyndroms
Sommer, C., Häuser, W., Alten, R., Petzke, F. W., Späth, M., Tölle, T. R., Üçeyler, N., Winkelmann, A., Winter, E., & Bär, K. (2012) · Der Schmerz · doi:10.1007/s00482-012-1172-2 · Cited by 79 · cited 1×
“did not find them of proven benefit [70], and hence, they are not included in the revised 2016 EULAR recommendations [6].”
Background
Association between alcohol consumption and symptom severity and quality of life in patients with fibromyalgia
Kim, C. H., Vincent, A., Clauw, D. J., Luedtke, C. A., Thompson, J. M., Schneekloth, T. D., & Oh, T. H. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4200 · Cited by 77 · cited 1×
“+e same association was not observed in heavy drinkers [59].”
Background
A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy
Chang, R. C., Rota, C., Glover, R. E., Mason, R. P., & Hong, J. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02267-2 · Cited by 73 · cited 1×
“Inhibition of microglial activation by naltrexone or naloxone therefore has an anti-inflammatory effect through the decrease in production of neurotoxic chemicals [66, 67], which is suggested to contribute to its analgesic effect [25].”
Background
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model
Barnes, N. S. A., Mitchell, V. A., Kazantzis, N. P., & Vaughan, C. W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13337 · Cited by 72 · cited 1×
“Endocannabinoids such as anandamide are metabolized by specific enzymes including fatty acid amide hydrolase (FAAH) and monacylglycerol lipase (MAGL), and agents capable of inhibiting these enzymes are being tested as novel analgesic targets [78].”
Background
The Intravenous Ketamine Test Predicts Subsequent Response to an Oral Dextromethorphan Treatment Regimen in Fibromyalgia Patients
Cohen, S. P., Verdolin, M. H., Chang, A. S., Kurihara, C., Morlando, B. J., & Mao, J. (2006) · Journal of Pain · doi:10.1016/j.jpain.2005.12.010 · Cited by 66 · cited 1×
“Ketamine, an NMDA antagonist, was found to reduce muscular and referred pain in FMS patients [30].”
Background
Management of fibromyalgia syndrome – an interdisciplinary evidence-based guideline
Häuser, W., Arnold, B., Eich, W., Felde, E., Flügge, C., Henningsen, P., Herrmann, M., Köllner, V., Kühn, E., Nutzinger, D. O., et al. (2008) · Europe PMC (PubMed Central) · doi:10.3205/000059 · Cited by 60
Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey
Weber, J., Schley, M. T., Casutt, M., Gerber, H., Schuepfer, G., Rukwied, R., Schleinzer, W., Ueberall, M. A., & Konrad, C. J. (2009) · Anesthesiology Research and Practice · doi:10.1155/2009/827290 · Cited by 56 · cited 2×
“showed dronabinol significantly reduce pain and depressive symptoms in FMS patients with neuropathic pain [29].”
Background
NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory
Khan, M. A., Houck, D. R., Gross, A. L., Zhang, X.-L., Cearley, C. N., Madsen, T. M., Kroes, R. A., Stanton, P. K., Burgdorf, J. S., & Moskal, J. R. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx096 · Cited by 56 · cited 1×
“+is finding led to the hypothesis that it would be effective in NMDA receptorassociated CNS disorders [83].”
Background
Fibromyalgia Syndrome: A Discussion of the Syndrome and Pharmacotherapy
Smith, H. S., & Barkin, R. L. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181df8e1b · Cited by 55 · cited 2×
“Comorbid conditions, including mood disorders, anxiety, headaches, irritable bowel syndrome, sleep disturbances, and chronic fatigue syndrome, are found in a large percentage of FMS patients [2, 44, 45].”
Background
Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF
Beyreuther, B. K., Geis, C., Stöhr, T., & Sommer, C. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.01.012 · Cited by 51 · cited 1×
“In animal models, it effectively reduced muscular hyperalgesia and was more effective than gabapentin and pregabalin [54].”
Background
Adherence and Persistence with Drug Therapy among Fibromyalgia Patients: Data from a Large Health Maintenance Organization
Shor, D. B., Weitzman, D., Dahan, S., Gendelman, O., On, Y. B., Amital, D., Shalev, V., Chodick, G., & Amital, H. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.170098 · Cited by 49 · cited 2×
“NYX-2925 ((2S,3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo2,5-diazaspiro[3,4]octan-2-yl)butanamide) is a new NMDA receptor modulator which was shown by Khan et al.”
Background
Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial
Calandre, E. P., Rico‐Villademoros, F., Galan, J. L., Molina-Barea, R., Vilchez, J. S., Rodriguez-lopez, C. M., Hidalgo‐Tallon, J., & Morillas-Arques, P. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3422-0 · Cited by 48
THE EFFECT OF ETHANOL ON THE CONCENTRATION OF γ-AMINOBUTYRIC ACID IN THE RAT BRAIN
Gordon, E. R. (1967) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y67-107 · Cited by 46
Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen‐week, randomized, double‐blind, placebo‐controlled, multicenter clinical trial
Arnold, L. M., Hirsch, I., Sanders, P. W., Ellis, A., & Hughes, B. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34390 · Cited by 42 · cited 1×
“Selective noradrenaline reuptake inhibitors (NRIs), such as reboxetine and its enantiomer esreboxetine, were also suggested as possible treatments for FMS, while the body of evidence regarding the efficacy of reboxetine is rather sporadic and is based mostly on case reports [13], esreboxetine was shown to reduce pain,…”
Background
Mirtazapine for fibromyalgia in adults
Welsch, P., Bernardy, K., Derry, S., Moore, A., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012708.pub2 · Cited by 38
Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study
Arnold, L. M., Whitaker, S., Hsu, C., Jacobs, D. R., & Merante, D. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1629757 · Cited by 33
Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
Smith, S. C., & Wagner, M. (2014) · PubMed · Cited by 32
Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: Results of a twelve‐week, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
Distler, O., Eich, W., Dokoupilová, E., Dvorak, Z., Fleck, M., Gaubitz, M., Hechler, M., Jansen, J., Krause, A., Bendszus, M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25062 · Cited by 29 · cited 1×
“With most evidence about the benefit of dopaminergic agonists being sporadic, it is worth mentioning tergulide, which in a randomized, double-blind placebo-controlled trial, was found to improve FMS symptoms in a subgroup of patients with spinal stenosis (as opposed to the comparing all tergulide-assigned patients to…”
Background
Analgesic effects of mirogabalin, a novel ligand for α2δ subunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia
Saeki, K., Yasuda, S.-I., Kato, M., Kano, M., Domon, Y., Arakawa, N., & Kitano, Y. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01628-z · Cited by 29 · cited 1×
“A newer gabapentinoid, mirogabalin (DS-5565) was shown to have analgesic qualities in animal models of both central and peripheral neuropathies [56], while approved for the treatment of peripheral neuropathy in Japan, its development as a treatment modality for FMS in the USA and Europe was stopped after it failed in…”
Background
A systematic review and meta‐analysis of memantine for the prevention or treatment of chronic pain
Kurian, R., Raza, K., & Shanthanna, H. (2019) · European Journal of Pain · doi:10.1002/ejp.1393 · Cited by 28 · cited 1×
“A recent meta-analysis of 15 studies regarding the benefit of memantine in treating chronic pain (either neuropathic or FMS) concluded that the current evidence regarding memantine for chronic pain is limited and reported an increase in dizziness as a side effect of the medication [34].”
Background
NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain
Ghoreishi-Haack, N. S., Priebe, J. M., Aguado, J. D., Colechio, E. M., Burgdorf, J. S., Bowers, M. S., Cearley, C. N., Khan, M. A., & Moskal, J. R. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.249409 · Cited by 27 · cited 2×
“Animal models, pending clinical trials in humans [35, 36] Pain Research and Management 3”
BackgroundMethod
Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: A novel analgesic and neuroprotective strategy?
Recla, J. M., & Sarantopoulos, C. D. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.01.052 · Cited by 26 · cited 1×
“A double-blind, randomized-controlled trial published in 2014 found memantine to achieve a significant reduction in pain [33], with another hypothesis suggesting the combined use of pregabalin and memantine to concomitantly affect voltage-gated calcium channels and NMDA receptors, as a possible therapeutic approach [8…”
Background
NYX ‐2925, A Novel N‐methyl‐D‐aspartate Receptor Modulator: A First‐in‐Human, Randomized, Double‐blind Study of Safety and Pharmacokinetics in Adults
Houck, D. R., Sindelar, L., Sanabria, C. R., Stanworth, S. H., Krueger, M., Suh, M., & Madsen, T. M. (2018) · Clinical and Translational Science · doi:10.1111/cts.12584 · Cited by 22 · cited 2×
“Animal models, pending clinical trials in humans [35, 36] Pain Research and Management 3”
BackgroundMethod
Mirtazapine for fibromyalgia in adults
Welsch, P., Bernardy, K., Derry, S., Moore, R. A., & Häuser, W. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012708 · Cited by 20
An update on emerging drugs for fibromyalgia treatment
Atzeni, F., Gerardi, M. C., Masala, I. F., Alciati, A., Batticciotto, A., & Sarzi‐Puttini, P. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1418323 · Cited by 17 · cited 1×
“+us, medications that modulate levels of these neurotransmitters in the CNS have the potential to improve CPM and reduce central sensitization [40, 41].”
Background
A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study
Konuk, N., Ortancıl, Ö., Bostancı, B., Kıran, S., & Sapmaz, P. (2010) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.1080/10177833.2010.11790631 · Cited by 11
THU0325 TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization
Lederman, S. M., Clauw, D. J., Gendreau, J., Arnold, L. M., Moldofsky, H., Mease, P. J., Daugherty, B. L., & Gendreau, R. M. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-eular.2014 · Cited by 6 · cited 1×
“8mg) has been reported to improve nonrestorative sleep in FMS patients [19]; however, this formulation has 2 Pain Research and Management”
Background

Flagged first, then by citations

Research works printed but not linked: 4

2008, German Medical Science, 6
2000, Journal of Pharmacology and Experimental Therapeutics, 293, 607
2014, Neuroendocrinology Letters, 35, 198
2011, PLoS One, 6

Sorted by citations

Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update
Siracusa, R., Paola, R. D., Cuzzocrea, S., & Impellizzeri, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083891 · Cited by 768
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 393
Management of Fibromyalgia: An Update
Jones, E. A., Asaad, F. S., Patel, N., Jain, E., & Abd-Elsayed, A. A. (2024) · Biomedicines · doi:10.3390/biomedicines12061266 · Cited by 82
“In a double-blind randomized trial, memantine was found to produce a significant reduction in pain, with a hypothesis that the combination of memantine with pregabalin could achieve therapeutic results in the treatment of fibromyalgia [47].”
Background
Pain Biomarkers in Fibromyalgia Syndrome: Current Understanding and Future Directions
Favretti, M., Iannuccelli, C., & Franco, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310443 · Cited by 71
A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?
Khurshid, H., Qureshi, I. A., Jahan, N., Went, T. R., Sultan, W., Sapkota, A., & Alfonso, M. (2021) · Cureus · doi:10.7759/cureus.17332 · Cited by 59
“Regarding the complex function of the endocannabinoid system in pain modulation, it is hypothesized that lack of endocannabinoids activity is among the underlying pathophysiology of FM but there is no clear evidence to support this assumption [1,9,11,15].”
BackgroundInfluential

See all 122

Authors: Tzadok, R., & Ablin, J. N.
Affiliations: Tel Aviv University (IL)
Corresponding author: Tzadok, Roie
ORCID: Tzadok, Roie
Ablin, Jacob N.
Venue: Pain Research and Management
Publisher: Wiley
Published: 2020-02-11
Volume: 2020
Pages: 1-9
ISSN: 1203-6765 (ISSN-L)
1918-1523
DOI: 10.1155/2020/6541798
PMC: PMC7036118
OpenAlex: W3005953215
Cited by: 122
References: 86
Citations by year: 2026: 7 · 2025: 24 · 2024: 25 · 2023: 23 · 2022: 24 · 2021: 13 · 2020: 6
FWCI: 2.73
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Pain Research and Management (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords: fibromyalgia, pharmacotherapy, pregabalin, duloxetine, milnacipran, conditioned pain modulation, cognitive impairment, pain processing, cannabinoid therapy, opioid therapy, personalized treatment, functional imaging
MeSH terms: Analgesics, Female, Fibromyalgia, Humans, Chronic Pain, Pain Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Current and Emerging Pharmacotherapy for Fibromyalgia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks